Bellerophon Therapeutics Receives EC Certification for New INOpulse® Drug-Device Delivery System
19 janv. 2016 08h03 HE
|
Bellerophon Therapeutics LLC
WARREN, N.J., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has received EC Certification...
Bellerophon Reports 2015 Third Quarter Operational and Financial Results
12 nov. 2015 06h03 HE
|
Bellerophon Therapeutics LLC
Phase 3 trial for patients with PAH on track to start enrollment by year-end Special Protocol Assessment (SPA) issued by FDA for Phase 3 program Company plans to continue Phase 2 testing in COPD...
Bellerophon Announces Functional Respiratory Imaging Data From Company Sponsored Clinical Trial of INOpulse(R) in COPD Patients With Pulmonary Hypertension Presented Today at the European Respiratory Society (ERS) International Congress
30 sept. 2015 07h03 HE
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, announced that an oral presentation of late-breaking data from...
Bellerophon Therapeutics Announces Positive Data From Interim Analysis of Phase 2 Long-Term Extension Study of INOpulse(R) for Treatment of Pulmonary Arterial Hypertension
24 sept. 2015 16h30 HE
|
Bellerophon Therapeutics LLC
Conference Call/Webcast to Be Held September 25, 2015 at 9:00am ET
Interim Data Reinforces Earlier Phase 2 Data and Indicates Sustainability of Benefits for PAH Patients
FDA Issues a Special...
Bellerophon Therapeutics Announces Leadership Team Changes
15 sept. 2015 08h07 HE
|
Bellerophon Therapeutics LLC
- Confirms Focus on Developing INOpulse® Nitric Oxide Therapy for Patients with Pulmonary Hypertension -
- Headcount and Costs Substantially Reduced -
HAMPTON, N.J., Sept. 15, 2015 (GLOBE...
Bellerophon to Present in Upcoming Investor Conferences
03 sept. 2015 16h23 HE
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Chairman and Chief Executive Officer...
Bellerophon Reports 2015 Second Quarter Operational and Financial Results
13 août 2015 18h33 HE
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported operational and financial results for the second...
Bellerophon Therapeutics Expands License Agreement With INO Therapeutics to Develop INOpulse(R) for Three Additional Cardiopulmonary Diseases
29 juil. 2015 06h03 HE
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., July 29, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has expanded its license agreement with...
Bellerophon Therapeutics Announces Top-Line Results From PRESERVATION I Clinical Trial for Bioabsorbable Cardiac Matrix (BCM)
27 juil. 2015 06h00 HE
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., July 27, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical stage biotherapeutics company with programs focused on the treatment of cardiopulmonary and...
Bellerophon Therapeutics Announces Management and Board Additions
01 juil. 2015 07h32 HE
|
Bellerophon Therapeutics LLC
HAMPTON, N.J., July 1, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointments of Amit Agrawal as Chief...